AzTrials
AzTrials

Neuroendocrine TumorsNCT03022188

Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma

An observational study of Neuroendocrine Tumors, run by Société Française d'Endoscopie Digestive at 22 sites in 2 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Neuroendocrine tumors (NETs) and carcinomas account for 10-15 % of all pancreatic incidentalomas. The management of pancreatic NETs depends on tumor stage and on presence or not of hormonal syndrome. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Neuroendocrine Tumors
How many people
100 participants
Where
22 sitesin 2 countries
Study dates
10 Jan 2017to Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patient with pancreatic tumors <2cm (stage 1 discovered incidentally.

Who may be able to join

  • patients older than 18 years old
  • with a small size ≤ 2 cm (stage I) non-functioning pancreatic neuroendocrine incidentaloma, cytologically and/or histologically proved or, in case of impossibility to obtain a cyto-histological specimen, with highly suggested diagnosis by imaging (early, homogenous enhancement at computerized tomography (CT- scan) and/or magnetic resonance Imaging (MR)I and positivity at somatostatin receptor scintigraphy (SRS))
  • patient ASA 1-2 (assessed according to ASA physical status classification system of American Society of Anesthesiology)
  • after geriatric evaluation for the patients older than 75 y.o
  • affiliated to a social security system
  • with signed consent for study enrolment.

Who cannot join

  • Patients < 18 years old
  • Patients with NET with size > 2 cm ( stage II-IV) or NEC and/or with presence of signs suspicious of malignancy
  • Patients with a functioning NET or NEC (clinical syndrome caused by excess hormonal secretion, as insulinoma or Zollinger -Ellison syndrome)
  • Patients with multiple pancreatic neuroendocrine tumors
  • Patients with multiple endocrine neoplasia type 1 (MEN1)
  • Patients with suspicion of non- neuroendocrine tumor
Show all 11Show fewer
  • Patient ASA 3-4 (assessed according to ASA physical status classification system of American Society of Anesthesiology)
  • Patients with other malignant disease under treatment or with under 5 years remission, except in situ or intramucosal carcinoma.
  • Pregnant or breastfeeding women
  • Patients judged not able to perform the monitoring
  • Absence of signed consent for study enrolment

Trial locations and contacts

22 sites in 2 countries.

22 sites in 2 countries

France21 sites
  • Hopital Sud

    Amiens

  • CHU Angers

    Angers

  • CHRU Jean Minjoz

    Besançon

  • Hopital du Haut Leveque

    Bordeaux

  • Hopital Beaujon

    Clichy

  • Hopital Bocage central

    Dijon

  • Centre Hospitalier Lyon Sud

    Lyon

  • Hopital Edouard Herriot

    Lyon

  • Hopital Privé Jean Mermoz

    Lyon

  • Hopital de la Timone

    Marseille

  • Hopital Nord

    Marseille

  • Hopital Privé Européen

    Marseille

  • Hopital Saint Joseph

    Marseille

  • Institut Paoli Calmette

    Marseille

  • Hotel Dieu

    Nantes

  • Hopital de l'archet 2

    Nice

  • Clinique du Trocadero

    Paris

  • Hopital Cochin

    Paris

  • Hopital Européen George Pompidou

    Paris

  • Hopital Robert Debré

    Reims

  • CHU Rangueil

    Toulouse

Other trials in France

Belgium1 site
  • Clinique Universitaire Saint Luc

    Leuven

Other trials in Belgium

About this study

Official title: Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma: Clinical and Morphological Findings, and Therapeutic Options (IPANEMA)

Neuroendocrine tumors (NETs) and carcinomas account for 10-15 % of all pancreatic incidentalomas. The management of pancreatic NETs depends on tumor stage and on presence or not of hormonal syndrome. The therapeutic approach for hormonally functional tumor, or large tumor (> 2 cm) with local, vascular or lymph nodes invasion, highly suggestive of malignancy, or in presence of metastasis, is well admitted: surgery is indicated or should be discussed. However, the attitude is less consensual for small (≤ 2 cm) non-functioning (NF) and non-metastatic lesions. In English, American or French recommendations, systematic surgical resection with lymphadenectomy is currently recommended in all medically fit patients. The follow-up (FU) is possible for tumors <2 cm (T1) located in the pancreatic head and for which enucleation is not feasible. Several recently published retrospective studies discuss the "non- surgical" management of the small NF incidentally detected pancreatic NETs (IPNETs) and highlight the necessity of developing guidelines for management of these patients. A strict correlation between tumor size and malignancy of these tumors was demonstrated in the single-center retrospective Italian study of Bettini and col., which included all patients with NF PNETs who underwent curative (R0) resection during 18 years. In the group of 51 patients with small size of T (2 cm or less), incidentally discovered, the majority of lesion was benign, and the authors concluded that follow-up can be proposed in patients with incidentally discovered NF PNETs ≤ 2 cm. However in despite of small size and asymptomatic character of the tumor, the rate of malignancy of NF IPNETs ≤ 2 cm was estimated to be 24 % (in 18% and 6% of cases, uncertain behaviour and carcinoma were present). Given the inherent morbidities associated with pancreatic surgery, a risk-benefit calculation may favour surveillance rather than surgery in highly selected patients. Thus, a better understanding of NF IPNETs and identification of their prognostic factors can be of help to select a subgroup of patients who could benefit from a long-term surveillance rather than a systematic surgical resection. Clearly, large prospective trials are needed to validate this approach.

Read the detailed description

With increasing use of high-resolution conventional imaging, pancreatic incidentalomas are being diagnosed more frequently. In two recent surgical series, neuroendocrine tumors (NETs) and carcinomas account for 10-15 % of all pancreatic incidentalomas, the majority ( 75-90 % of cases) well differentiated. The factors affecting the behaviour of pancreatic NETs are differentiation, histological grade, staging, size and intratumoral microvascular density. In updated World Health Organization (WHO) classification, the grading system is based on tumor differentiation, the rate of proliferation and Ki-67 index. The management of pancreatic NETs depends on tumor stage and on presence or not of hormonal syndrome. By definition, the incidentally discovered pancreatic NETs (PNETs) are unassociated with hormonal syndromes (nonfunctioning) and detected in patients who undergo diagnostic evaluations for unrelated conditions.

The therapeutic approach for hormonally functional tumor, or large tumor (> 2 cm) with local, vascular or lymph nodes invasion, highly suggestive of malignancy, or in presence of metastasis, is well admitted: surgery is indicated or should be discussed.

However, the attitude is less consensual for small (≤ 2 cm) non-functioning (NF) and non-metastatic lesions. There is a paucity of literature reporting pancreatic neuroendocrine incidentalomas and their characteristics. However, given their increased incidence, they are an emerging problem and require changes in treatment guidelines. In English, American or French recommendations, systematic surgical resection with lymphadenectomy is currently recommended in all medically fit patients. The follow-up (FU) is possible for tumors <2 cm (T1) located in the pancreatic head and for which enucleation is not feasible. This therapeutic approach has two limitations: 1) the significant incidence of these tumors, because of the widespread use of routine imaging, and the improved technology of multi detector CT scan, the fortuitous discovery of small pancreatic incidentalomas is becoming more common. 2) Pancreatic surgery carries significant postoperative morbidity even in high-volume tertiary centers and even in parenchyma-preserving resection. This may results in many pancreatic resections for tumors with unknown natural history. On the other hand, the follow-up may be a factor of considerable anxiety, and carries the risk, actually difficult to assess, to let the tumor grow between two monitoring controls, with the possible evolution to the irreversible metastatic stage of the disease.

As a result, the investigators are unceasingly facing a dilemma: how to manage asymptomatic patients with small incidentally detected, potentially benign NETs? Several recently published retrospective studies discuss the "non- surgical" management of the small NF incidentally detected pancreatic NETs (IPNETs) and highlight the necessity of developing guidelines for management of these patients. A strict correlation between tumor size and malignancy of these tumors was demonstrated in the single-center retrospective Italian study of Bettini and col. , which included all patients with NF PNETs who underwent curative (R0) resection during 18 years. In the group of 51 patients with small size of T (2 cm or less), incidentally discovered, the majority of lesion was benign, and the authors concluded that follow-up can be proposed in patients with incidentally discovered NF PNETs ≤ 2 cm. However in despite of small size and asymptomatic character of the tumor, the rate of malignancy of NF IPNETs ≤ 2 cm was estimated to be 24 % (in 18% and 6% of cases, uncertain behaviour and carcinoma were present).

Given the inherent morbidities associated with pancreatic surgery, a risk-benefit calculation may favour surveillance rather than surgery in highly selected patients. Thus, a better understanding of NF IPNETs and identification of their prognostic factors can be of help to select a subgroup of patients who could benefit from a long-term surveillance rather than a systematic surgical resection. Clearly, large prospective trials are needed to validate this approach.

Keywords
pancreatic incidentaloma, pancreatic neuroendocrine tumor, EUS-guided fine-needle aspiration, contrast-enhanced endoscopic ultrasound
Medical subject headings
Neuroendocrine Tumors, Adenoma, Islet Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03022188
Study groupRoleWhat they receive
ObservationalObservational

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. rate of malignancy among nonfunctioning (NF) small (≤ 2 cm) pancreatic neuroendocrine incidentalomas (PNEI).

    • any G3 tumor *
    • G2 * or G1 * tumor with lymph node metastases and / or distant metastasis
    • G2 or G1 tumor with recurrence during the clinical and morphological surveillance after surgical treatment

    Measured: 36 months

Secondary outcomes (16)
  1. progression rate among NF-PNEI ≤ 2cm in case of non-surgical management

    • significant increase of tumor size within one year > 20% on radiological examination or > 2 mm at endoscopic ultrasound ; - appearance of metastatic lymph nodes and / or distant metastases

    Measured: 36 months

  2. determination of Ki67 value

    determination of Ki67 value on cytological samples obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and on surgical specimen

    Measured: 36 months

  3. performance of contrast harmonic endoscopic ultrasound (CH-EUS) for the diagnosis of malignancy

    assessment of sensibility (Se), specificity (Spe), positive predictive value (PPV), negative predctive value (NPV) and accuracy of CH-EUS for the diagnosis of malignancy, appreciated by tumor microvascularisation assessment during CH-EUS procédures and correlation with tumor microvascular density appreciated on surgical specimen

    Measured: 36 months

  4. rate of surgical treatment, delay from diagnosis to surgery and rationale

    number of patients having undergone surgical treatment / total number of patients included in the study ; - number of days between diagnosis and surgical treatment ,

    Measured: 36 months

  5. the rate of non-surgical management and the reasons that determined the choice of this therapeutic option

    • number of patients with non- surgical management (monitoring) / total number of patients included in the study

    Measured: 36 months

  6. to assess the morbidity among the patients with surgical treatment

    -Morbidity defined as all complication occurring after surgical resection until discharge and/or readmission, and will be grade according to the Clavien-Dindo classification. Postoperative pancreatic fistula, haemorrhage, and delayed gastric emptying were defined according to the International Study Group of Pancreatic Surgery

    Measured: 36 months

  7. to assess the mortality among the patients with surgical treatment

    Perioperative mortality is death in relation to surgery, defined as death after surgical resection until discharge and/or readmission

    Measured: 36 monts

  8. to assess the overall survival (OS) among the patients with surgical treatment

    OS defined as the time from diagnosis to death of any cause

    Measured: 36 months

  9. disease specific survival (DSS) among the patients with surgical treatment

    DSS defined as the time from diagnosis to disease-related death and censored at the last follow-up date if no events had occurred.

    Measured: 36 months

  10. to assess the progression-free survival (PFS) among the patients with surgical treatment

    PFS is the period during and after treatment in which a participant is living with a disease that does not get worse defined and is defined as the time from diagnosis until 1) loco-regional or systemic recurrence, 2) second malignancy, or 3) death from any cause; late deaths not related to cancer or its treatment are excluded

    Measured: 36 months

  11. to assess the morbidity among the patients with non-surgical treatment

    morbidity defined as all complication occurred after endoscopic ultrasound procedures until discharge and/or readmission

    Measured: 36 months

  12. to assess the mortality among the patients with non-surgical treatment

    mortality defined as death in relation to endoscopic ultrasound procedure, occured until discharge and/or readmission

    Measured: 36 months

  13. to assess the overal survival (OS) among the patients with non-surgical treatment

    OS defined as the time from diagnosis to death of any cause

    Measured: 36 months

  14. to assess the disease free survival (DSS) among the patients with non-surgical treatment

    DSS defined as the time from diagnosis to disease-related death and censored at the last follow-up date if no events had occurred.

    Measured: 36 months

  15. to assess the progression-free survival (PFS) among the patients with non-surgical treatment

    PFS is the period during and after treatment in which a participant is living with a disease that does not get worse defined and is defined as the time from diagnosis until 1) loco-regional or systemic recurrence, 2) second malignancy, or 3) death from any cause; late deaths not related to cancer or its treatment are excluded

    Measured: 36 months

  16. Quality of life assessment at baseline, 12, 24 and 36 months

    The quality of life will be assessed using the 12-item Short-Form Health Survey (SF12) self- questionnaire

    Measured: baseline, 12, 24 and 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jan 2017 (estimated)
  2. Study start10 Jan 2017
  3. Primary completionJul 2022
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03022188
Sponsor's protocol ID
CAL-201557
Status last verified
Sep 2022
First submitted
10 Jan 2017
Last updated
21 Feb 2024
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Neuroendocrine Tumors, run by Société Française d'Endoscopie Digestive at 22 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 21 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 22 sites in France, Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

rate of malignancy among nonfunctioning (NF) small (≤ 2 cm) pancreatic neuroendocrine incidentalomas (PNEI). (time frame: 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in